OrthoPediatrics stock recently saw its consensus analyst price target lowered from $26.29 to $24.14. This change reflects a more cautious stance from the investment community. The adjustment comes ...
In the assessment of 12-month price targets, analysts unveil insights for CoreWeave, presenting an average target of $151.73, ...
Intellia Therapeutics (NASDAQ: NTLA) underwent analysis by 21 analysts in the last quarter, revealing a spectrum of ...
TipRanks on MSN
Madrigal Pharmaceuticals presents new data on Rezdiffra
Madrigal Pharmaceuticals (MDGL) announced positive two-year data from the open-label compensated MASH cirrhosis arm of the Phase 3 MAESTRO-NAFLD-1 ...
Q3 2025 Earnings Call November 6, 2025 8:30 AM ESTCompany ParticipantsVipin Garg - President, CEO & DirectorLinda Richardson ...
Q3 2025 Management View John Oyler, Co-Founder, Executive Chairman & CEO, described Q3 as a period of "another strong quarter ...
4 天on MSN
Iovance targets $1B-plus U.S. peak sales for Amtagvi as manufacturing shifts to internal ...
Discover key insights from Iovance Biotherapeutics' Q3 2025 earnings call—including revenue growth, margin gains, and pipeline updates.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈